JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Transvascular balloon dilation for neonatal critical aortic stenosis: early and midterm results.
Journal of the American College of Cardiology 1997 Februrary
OBJECTIVES: We evaluated our immediate and midterm (mean 4.3 years) results of balloon dilation of critical valvular aortic stenosis in 33 neonates.
BACKGROUND: Balloon dilation has been used as an alternative to surgical treatment. Reports to date consist of small series (largest 16 babies) with short-term follow-up (longest 4.8 years).
METHODS: From 1985 to 1991, 33 neonates had dilation at a mean age of 13 days and a mean weight of 3.4 kg. Nineteen of the neonates (58%) were intubated and received prostaglandins, and 94% had other cardiac abnormalities.
RESULTS: The dilation was completed retrograde in 31 of the neonates (umbilical artery in 11 and femoral artery in 20) and anterograde (femoral vein) in 2. The average immediate peak gradient and left ventricular end-diastolic pressure reductions were 54% and 20%, respectively. The overall mortality rate was 12% (three early deaths and one late). All 20 neonates dilated through a femoral artery initially had pulse loss with restoration in 35% after thrombolytic therapy. At 8.3 years, survival and freedom of reintervention probability rates were 88% and 64%, respectively. At mean 4.3 years of follow-up, 83% of the survivors were asymptomatic; Doppler study revealed a maximal instantaneous gradient < 50 mm Hg in 65% of neonates and significant aortic regurgitation in 14%.
CONCLUSIONS: This study confirms that dilation of aortic stenosis in neonates is effective; reintervention (mostly redilation) is frequent (40%); and midterm survival is encouraging (88%).
BACKGROUND: Balloon dilation has been used as an alternative to surgical treatment. Reports to date consist of small series (largest 16 babies) with short-term follow-up (longest 4.8 years).
METHODS: From 1985 to 1991, 33 neonates had dilation at a mean age of 13 days and a mean weight of 3.4 kg. Nineteen of the neonates (58%) were intubated and received prostaglandins, and 94% had other cardiac abnormalities.
RESULTS: The dilation was completed retrograde in 31 of the neonates (umbilical artery in 11 and femoral artery in 20) and anterograde (femoral vein) in 2. The average immediate peak gradient and left ventricular end-diastolic pressure reductions were 54% and 20%, respectively. The overall mortality rate was 12% (three early deaths and one late). All 20 neonates dilated through a femoral artery initially had pulse loss with restoration in 35% after thrombolytic therapy. At 8.3 years, survival and freedom of reintervention probability rates were 88% and 64%, respectively. At mean 4.3 years of follow-up, 83% of the survivors were asymptomatic; Doppler study revealed a maximal instantaneous gradient < 50 mm Hg in 65% of neonates and significant aortic regurgitation in 14%.
CONCLUSIONS: This study confirms that dilation of aortic stenosis in neonates is effective; reintervention (mostly redilation) is frequent (40%); and midterm survival is encouraging (88%).
Full text links
Trending Papers
Carvedilol, probably the β-blocker of choice for everyone with cirrhosis and portal hypertension: But not so fast!Liver International : Official Journal of the International Association for the Study of the Liver 2023 June
The five types of glomerulonephritis classified by pathogenesis, activity, and chronicity (GN-AC).Nephrology, Dialysis, Transplantation 2023 May 23
Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management.Endocrine Reviews 2023 March 29
American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.Gastroenterology 2023 June
The future of intensive care: the study of the microcirculation will help to guide our therapies.Critical Care : the Official Journal of the Critical Care Forum 2023 May 17
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app